Molecular Insight receives 10th extension of waiver agreement with bond holders
Molecular Insight Pharmaceuticals, a biopharmaceutical company discovering and developing targeted therapeutic and imaging radiopharmaceuticals for use in oncology, has received a 10th extension of its waiver agreement with its bond holders, allowing debt restructuring discussions to continue.
The long awaited final omnibus rule removes significant barriers to clinical research by allowing the use of compound authorizations and authorization for the future use or disclosure of protected health information.